UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Annals of oncology, 2024-05, Vol.35 (5), p.448-457

2024

Volltextzugriff (PDF)

Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

ESMO Gastrointestinal Oncology, 2024-03, Vol.3, p.100030, Article 100030

2024

Volltextzugriff (PDF)

1632P Organoids as tools for functional precision oncology in advanced pancreatic cancer

Annals of oncology, 2023-10, Vol.34, p.S903-S904

2023

Volltextzugriff (PDF)

External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification

European journal of surgical oncology, 2023-08, Vol.49 (8), p.1481-1488

2023

Volltextzugriff (PDF)

PD-10 Organoids as tools for functional precision oncology in advanced pancreatic cancer

Annals of oncology, 2023-06, Vol.34, p.S4-S5

2023

Volltextzugriff (PDF)

P-131 Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma

Annals of oncology, 2023-06, Vol.34, p.S61-S62

2023

Volltextzugriff (PDF)

The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients

Digestive diseases and sciences, 2023-04, Vol.68 (4), p.1525-1528

2023

Volltextzugriff (PDF)

Mutations de l'ADN dans les cholangiocarcinomes : cibler IDH1 et autres mutations

Bulletin du cancer, 2022-11, Vol.109 (11), p.11S21-11S27

2022

Volltextzugriff (PDF)

343P DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)

Annals of oncology, 2022-09, Vol.33, p.S693

2022

Volltextzugriff (PDF)

387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study

Annals of oncology, 2022-09, Vol.33, p.S713-S714

2022

Volltextzugriff (PDF)

387MO Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial

Annals of oncology, 2021-09, Vol.32, p.S532-S533

2021

Volltextzugriff (PDF)

429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status

Annals of oncology, 2021-09, Vol.32, p.S548-S549

2021

Volltextzugriff (PDF)

404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)

Annals of oncology, 2020-09, Vol.31, p.S413-S413

2020

Volltextzugriff (PDF)

444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers

Annals of oncology, 2020-09, Vol.31, p.S430-S431

2020

Volltextzugriff (PDF)

LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial

Annals of oncology, 2020-09, Vol.31, p.S1152-S1152

2020

Volltextzugriff (PDF)

1047P Long terms efficacy of anti-PD(L)1 in MSI tumours

Annals of oncology, 2020-09, Vol.31, p.S717-S717

2020

Volltextzugriff (PDF)

Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position

European journal of cancer (1990), 2020-08, Vol.135, p.103-112

2020

Volltextzugriff (PDF)

FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

Annals of oncology, 2019-10, Vol.30, p.v214

2019

Volltextzugriff (PDF)

569PFUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

569P - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

Annals of oncology, 2019-10, Vol.30, p.v214-v214

2019

Volltextzugriff (PDF)

Traitement des néoplasmes neuroendocrines digestifs

Oncologie (Paris, France), 2019-05, Vol.21 (5-12), p.97-103

2019

Volltextzugriff (PDF)

Radiothérapie en conditions stéréotaxiques de cancers du pancréas localement évolués : résultats préliminaires d’une série de 16 patients à Gustave–Roussy

Cancer radiothérapie, 2018-10, Vol.22 (6-7), p.727-727

2018

Volltextzugriff (PDF)

Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial

Annals of oncology, 2017-09, Vol.28, p.v247-v247

2017

Volltextzugriff (PDF)

Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2569-2569

2017

Volltextzugriff (PDF)

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(144)
Mit Volltextzugriff
(171)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(54)
Science & Technology
(40)
Life Sciences & Biomedicine
(39)
Medicine
(33)
Biological And Medical Sciences
(27)
Female
(27)
Male
(27)
Sciences Biologiques Et Medicales
(24)
Medical Sciences
(23)
Sciences Medicales
(23)
Oncology
(20)
Middle Aged
(16)
Adult
(15)
Infant
(15)
Aged
(14)
Gastroenterology & Hepatology
(14)
Chemotherapy
(13)
Gastroenterologie. Foie. Pancreas. Abdomen
(12)
Gastroenterology. Liver. Pancreas. Abdomen
(12)
Treatment Outcome
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

Codon-specific KRAS mutations predict survival in advanced pancreatic cancer

1632P Organoids as tools for functional precision oncology in advanced pancreatic cancer

External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification

PD-10 Organoids as tools for functional precision oncology in advanced pancreatic cancer

P-131 Evaluation of predictive factors of toxicity of chemotherapy with FOLFIRINOX in patients treated for pancreatic adenocarcinoma

The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients

Mutations de l'ADN dans les cholangiocarcinomes : cibler IDH1 et autres mutations

343P DPYD gene sequencing and in silico functionality prediction of polymorphisms in 3,471 colorectal cancer patients treated with fluoropyrimidine (FP)

387P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: Final results of the randomized phase II TIME-PRODIGE 28 UNICANCER study

387MO Tumour mutation profiles and circulating tumour cells in metastatic colorectal cancer patients treated with FOLFIRI + cetuximab: A prospective ancillary study of the UNICANCER PRODIGE-28 trial

429P Maintenance treatment with cetuximab versus observation in RAS wild-type metastatic colorectal cancer: First results of the randomized phase II TIME-PRODIGE28 UNICANCER study according to RAS/BRAF status

404MO Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE individual patient data meta-analysis (IPD-MA)

444P PRODIGE 25 (FFCD 11-01)-FOLFA: A randomized phase II trial evaluating aflibercept associated with LV5FU2 regimen as first-line treatment of non-resectable metastatic colorectal cancers

LBA21 Neoadjuvant mFOLFIRINOX and preoperative chemoradiation (CRT) versus preoperative CRT in patients with T3-4 rectal cancer: Surgical and quality of life results of PRODIGE 23 phase III trial

1047P Long terms efficacy of anti-PD(L)1 in MSI tumours

Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position

FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

569PFUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

569P - FUSAFE individual patient data meta-analysis (MA) to assess the performance of dihydropyrimidine dehydrogenase (DPD) gene polymorphisms for predicting grade 4-5 fluoropyrimidine (FP) toxicity

Traitement des néoplasmes neuroendocrines digestifs

Radiothérapie en conditions stéréotaxiques de cancers du pancréas localement évolués : résultats préliminaires d’une série de 16 patients à Gustave–Roussy

Precision medicine for patients with advanced biliary tract cancers: Updated results from the prospective MOSCATO trial

Vitamin K epoxide reductase complex subunit 1 (VKORC1): A pharmacogenomic predictor of response and survival in patients (pts) on triplet hepatic artery infusion (HAI) and intravenous cetuximab (IV-Cet) for initially unresectable liver metastases from colorectal cancer (uLM-CRC) (EU trial OPTILIV)

Suchergebnisse filtern